fluvastatin

(redirected from Lescol xl)
Also found in: Dictionary, Thesaurus.
Related to Lescol xl: fluvastatin

fluvastatin

 [floo´vah-stat″in]
an inhibitor of cholesterol biosynthesis used as the sodium salt in the treatment of hyperlipidemia and to slow the progression of atherosclerosis associated with coronary heart disease.

fluvastatin

/flu·va·stat·in/ (floo´vah-stat″in) an inhibitor of cholesterol biosynthesis used as the sodium salt in the treatment of hyperlipidemia and to slow the progression of atherosclerosis associated with coronary heart disease.

fluvastatin

(flo͞o′və-stăt′n)
n.
A statin, C24H26FNO4, used in the form of its sodium salt, that blocks the body's synthesis of cholesterol and is administered especially to individuals who are at risk for heart disease.

fluvastatin

an antilipidemic.
indications It is used as an adjunct treatment in primary hypercholesterolemia (types Ia and Ib) and in coronary atherosclerosis associated with coronary artery disease.
contraindications Factors that prohibit its use include known hypersensitivity to this drug, pregnancy, lactation, and active liver disease.
adverse effects Life-threatening effects are liver dysfunction, myositis, rhabdomyolysis, thrombocytopenia, hemolytic anemia, and leukopenia. Other adverse effects include rash, pruritus, nausea, constipation, diarrhea, dyspepsia, flatus, pancreatitis, lens opacities, myalgia, headache, dizziness, insomnia, fatigue, influenza, upper respiratory infection, rhinitis, cough, pharyngitis, and sinusitis.

fluvastatin

Lescol® Cardiology An HMG-CoA reductase inhibitor/statin that improves lipid profile of Pts with hypercholesterolemia and mixed dyslipidemia Effect Slowing coronary ASHD in CAD by ↓ total-C, LDL-C, ↑ HDL-C, ↓ TGs Adverse events Rash. See LDL-C, Hypercholesterolemia, Statin.

fluvastatin

A statin drug (see STATINS) that blocks the synthesis of cholesterol in the body and can be used to lower unduly high blood cholesterol levels. A brand name is Lescol.
References in periodicals archive ?
In addition to Lescol and Lescol XL, Reliant's product portfolio includes: DynaCirc(R) (isradipine) and DynaCirc(R) CR (an extended-release formulation) for the treatment of hypertension; InnoPran(R) XL (propranolol HCl), the only bedtime-dosed beta-blocker for the treatment of hypertension; Rythmol(R) (propafenone) and Rythmol(R) SR (a controlled-release formulation), antiarrhythmic agents approved for the treatment of atrial fibrillation in patients without structural heart disease; Antara(TM) (fenofibrate) capsules approved for adjunct treatment of elevated cholesterol and triglycerides; and Omacor(R) (omega-3 ethyl esters), under an exclusive license agreement with Pronova Biocare AS, for the treatment of very high triglycerides.
In addition to the new indication, Lescol and Lescol XL are indicated to reduce elevated total cholesterol, LDL-C, TG and apolipoprotein B (Apo B) levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia.
Lescol capsules and Lescol XL tablets are well-tolerated prescription medications that should be used in conjunction with changes in diet, for the treatment of high cholesterol.
Reliant Pharmaceuticals, LLC, markets Lescol and Lescol XL in the United States through an agreement with Novartis Pharmaceuticals Corporation.
Lescol XL received FDA approval in October 2000 for use as an adjunct to diet to:
Treatment with Lescol and Lescol XL should be discontinued if myopathy or rhabdomyolysis are diagnosed or suspected.
Reliant Pharmaceuticals markets Lescol XL in the United States through an agreement with Novartis Pharmaceuticals Corporation.
LESCOL XL 80 mg, as recommended as a starting dose, is indicated as an adjunct to diet to reduce patients' elevated total cholesterol, LDL-C, TG and apolipoprotein B (Apo B) levels, and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia and to slow the progression of atherosclerosis in patients with coronary heart disease.
The FDA approved LESCOL XL 80mg based on their review of data from five controlled clinical trials that were four to 24 weeks in duration in more than 900 patients with Type IIa or IIb hyperlipoproteinemia.
In Phase III clinical trials, the overall incidence of adverse events for LESCOL XL was similar to LESCOL 40 mg, and no cases of myopathy or rhabdomyolysis were observed in these trials.
including a head-to-head comparison with LESCOL XL 80 mg versus atorvastatin 10 mg, simvastatin 40 mg and pravastatin 40 mg.
In clinical trials, adverse events to LESCOL and LESCOL XL 80 mg were generally mild and similar to placebo.